Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
Conditions
Interventions
Nalfurafine hydrochloride(MT-9938) 2.5μg
Nalfurafine hydrochloride(MT-9938) 5μg
+2 more
Locations
4
United States
Los Angeles, California, United States
New York, New York, United States
Rosedale, New York, United States
San Antonio, Texas, United States
Start Date
September 1, 2012
Primary Completion Date
March 1, 2014
Completion Date
March 1, 2014
Last Updated
February 9, 2022
NCT02143648
NCT05575193
NCT04470154
NCT03422653
NCT03998163
NCT00494975
Lead Sponsor
Toray Industries, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions